Kolexia
Villanueva Cristian Oncologie médicale
Villanueva Cristian
Oncologie médicale
Oncoclem
Saint-Jean-de-Védas, France
126 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Récidive tumorale locale Métastase lymphatique Neutropénie Carcinome épidermoïde Tumeurs de la prostate Carcinomes Tumeurs du sein triple-négatives

Collaborateurs

Voir plus
Pivot Xavier
Pivot Xavier
Centre Paul Strauss, Strasbourg, France
Chaigneau Loic
Chaigneau Loic
Le Mittan Annexe Du Hnfc, Montbéliard, France
Bazan Fernando
Bazan Fernando
Le Mittan Annexe Du Hnfc, Montbéliard, France
Dobi Erion
Dobi Erion
Hôpital Jean-Minjoz, Besançon, France

Industries

Voir plus
Novartis
36 collaboration(s)
Dernière en 2023
AstraZeneca
28 collaboration(s)
Dernière en 2023
Pfizer
20 collaboration(s)
Dernière en 2023
Lilly
18 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
JAMA oncology   10 août 2023
Diagnosis and management of interstitial lung disease induced by antibody-drug conjugates in breast cancer: A French expert opinion paper.
Bulletin du cancer   16 juin 2023
BOLERO-4: An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer
Essai Clinique (Novartis)   28 avril 2023
MONALEESA-2: A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Essai Clinique (Novartis)   25 avril 2023
Quelle interprétation et quel impact pour la pratique clinique?
Edimark   13 avril 2023
TROIKA: A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in Patients With HER2+ Early Breast Cancer
Essai Clinique (Prestige Biopharma Limited)   06 février 2023
Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.
BMC cancer   31 janvier 2023